> Back to EJC

Recent editions

  • March 2015
    Christopher Wild on the exposome, a measure of environmental exposure.
  • February 2015
    Mathematicians are developing a blood flow model for metastasis.
  • January 2015
    René Bernards on discovering effective drug combinations.
  • December 2014
    Research on the high rate of burnout among young oncologists.
  • November 2014
    Carl June on the efficacy of CAR-T cells in treating leukaemia.
  • October 2014
    News from ESMO 2014 with Solange Peters and Alexander Eggermont.
  • September 2014
    Discussing how healthcare systems can meet the needs of cancer survivors.
  • July/August 2014
    Sophie Postel-Vinay on new recommendations for phase 1 trials.
  • June 2014
    Hans Clevers on important research into stem cells in normal gut tissue.
  • May 2014
    Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
  • April 2014
    Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
  • March 2014
    The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
  • February 2014
    Charles Swanton on a study that maps genetic changes in cancers over time.

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – April 2013

Loading EJC News Focus video

What impact will an ageing population have in cancer?

The increasing burden of cancer in an ageing population is widely accepted, but more detailed discussion of the implications for patients, oncologists and healthcare systems is sometimes lacking. Elderly patients may of course need specific treatment approaches, but experts are calling for a more wide-ranging debate on measures that need to be put in place now to meet the needs of an ageing population. In this month's EJC News Focus, Richard Marais, David Cameron, Mary O'Brien, Roger Stupp, Manuela Schmidinger and Jan Willem Coebergh tell Helen Saul that it's time to re-look at screening and treatment guidelines, at survivorship issues, and the structures that will be needed to deal with co-morbidity.